Vaccine optimization for COVID-19: Who to vaccinate first?

Johns Hopkins University and Medicine Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (2020); https://coronavirus.jhu.edu/map.html.

10.1016/S0140-6736(20)31252-6

C. Zimmer J. Corum S.-L. Wee Coronavirus Vaccine Tracker (2020); https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.

R. Cohen, C. Jung, N. Ouldali, A. Sellam, C. Batard, F. Cahn-Sellem, A. Elbez, A. Wollner, O. Romain, F. Corrard, S. Aberrane, N. Soismier, R. Creidy, M. Smati-Lafarge, O. Launay, S. Bechet, E. Varon, C. Levy, Assessment of spread of SARS-CoV-2 by RT-PCR and concomitant serology in children in a region heavily affected by COVID-19 pandemic. medRxiv 2020.06.12.20129221 (2020).

10.1016/S0140-6736(20)31354-4

M. Twohey Who Gets a Vaccine First? U.S. Considers Race in Coronavirus Plans (2020).

Centers for Disease Control and Prevention 2009 H1N1 Flu (2009); www.cdc.gov/h1n1flu/vaccination/vaccinesupply.htm.

10.1126/science.abb8001

Moderna A phase 3 randomized stratified observer-blind placebo-controlled study to evaluate the efficacy safety and immunogenicity mRNA-1273 SARS-CoV-2 vaccine in adults aged 18 years and older (2020).

Pfizer A phase 1/2/3 placebo-controlled randomized observer-blind dose-finding study to evaluate the safety tolerability immunogenicity and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals (2020) pp. 1–137.

CDC COVID-19 Pandemic Planning Scenarios (2020); www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html.

N.M. Ferguson D. Laydon G. Nedjati-Gilani N. Imai K. Ainslie M. Baguelin S. Bhatia A. Boonyasiri Z. Cucunubá G. Cuomo-Dannenburg A. Dighe I. Dorigatti H. Fu K. Gaythorpe W. Green A. Hamlet W. Hinsley L. C. Okell S. van Elsland H. Thompson R. Verity E. Volz H. Wang Y. Wang Patrick GT Walker C. Walters P. Winskill C. Whittaker C. A. Donnelly S. Riley A. C. Ghani Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand (2020); https://doi.org/10.25561/77482.

Washington State Coronavirus Response COVID-19 risk assessment dashboard (2020); https://coronavirus.wa.gov/what-you-need-know/covid-19-risk-assessment-dashboard.

State of California COVID-19 data and tools (2020); https://covid19.ca.gov/data-and-tools/.

Centers for Disease Control and Prevention Final estimates for 2009–10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage August 2009 to May 2010 (2010); www.cdc.gov/flu/fluvaxview/coverage_0910estimates.htm.

Q.-L. Jing, M.-J. Liu, J. Yuan, Z.-B. Zhang, A.-R. Zhang, N. E. Dean, L. Luo, M. Ma, I. Longini, E. Kenah, Y. Lu, Y. Ma, N. Jalali, L.-Q. Fang, Z.-C. Yang, Y. Yang, Household secondary attack rate of COVID-19 and associated determinants. medRxiv 2020.04.11.20056010 (2020).

10.1016/S1473-3099(20)30287-5

10.1001/jamainternmed.2020.4130

10.1056/NEJMc2005073

10.1093/cid/ciaa201

N. G. Davies, A. J. Kucharski, R. M. Eggo, A. Gimma; CMMID COVID 19 working group, W. J. Edmunds, The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: A modelling study. Lancet 5, E375–E385 (2020).

10.7326/M20-0504

10.1056/NEJMoa2001316

10.3390/jcm9020538

10.1126/sciadv.abc1202

S. M. Bartsch, K. J. O’Shea, M. C. Ferguson, M. E. Bottazzi, S. N. Cox, U. Strych, J. A. McKinnell, P. T. Wedlock, S. S. Siegmund, P. J. Hotez, B. Y. Lee, How efficacious must a COVID-19 coronavirus vaccine be to prevent or stop an epidemic by itself. medRxiv 2020.05.29.20117184 (2020).

M. Makhoul, H. H. Ayoub, H. Chemaitelly, S. Seedat, G. R. Mumtaz, S. Al-Omari, L. J. Abu-Raddad, Epidemiological impact of SARS-CoV-2 vaccination: Mathematical modeling analyses. medRxiv 2020.04.19.20070805 (2020).

10.1016/0025-5564(78)90023-8

10.1126/science.1175570

10.1371/journal.pone.0013767

10.1056/NEJMc2025179

10.1038/s41591-020-0965-6

Centers for Disease Control and Prevention Assessing Risk Factors for Severe COVID-19 Illness (2020); https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html.

European Centre for Disease and Prevention and Control COVID-19 Clusters and Outbreaks in Occupational Settings in the EU/EEA and the UK (2020); www.ecdc.europa.eu/sites/default/files/documents/COVID-19-in-occupational-settings.pdf.

10.1001/jama.2020.8598

10.1001/jamanetworkopen.2020.21892

United States Census Bureau Washington (2020); https://data.census.gov/cedsci/profile?q=Washington&g=0400000US53.

Population Pyramid Population of United States of America 2020 (2020); www.populationpyramid.net/united-states-of-america/2020/.

10.1371/journal.pcbi.1005697

10.3201/eid2606.200357

10.1016/j.ijid.2020.02.060

10.1093/oxfordjournals.aje.a116498

M. E. Halloran I. M. Longini C. J. Struchiner Design and Analysis of Vaccine Studies (Springer 2010).

C. Audet W. Hare Derivative-Free and Blackbox Optimization (Cham Switzerland Springer 2017).

The Sage Developers SageMath the Sage Mathematics Software System (Version 9.1) (2020); www.sagemath.org.

S. Kotz N. Balakrishnan N.L. Johnson Continuous Multivariate Distributions (Models and Applications Wiley 2000) vol. 1.

10.1007/s10589-010-9329-3

10.1038/s41592-019-0686-2

10.1109/ICNN.1995.488968

10.21105/joss.00433

10.15585/mmwr.mm6914e1

10.3201/eid2610.201620

10.2807/1560-7917.ES.2020.25.10.2000180

10.1038/s41591-020-0869-5

10.1016/S0140-6736(20)30260-9

10.1016/j.ijid.2020.01.050